SCHEMBL20203460

SCHEMBL20203460

CC(C)c1ccc(N2CCN(C)CCC2=O)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
AKR1C3 P42330 2/20 0.36
CACNA2D1 P54289 5/20 0.35
SLC6A2 P23975 4/20 0.35
CCR6 P51684 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
DRD3 P35462 1/20 0.34
KCNH2 Q12809 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
ESR1 P03372 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
CCND3 P30281 1/20 0.33
CDK7 P50613 1/20 0.33
CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10256825 0.87 SLC6A2 (0.42) HPGDHRH3AKR1C3SLC6A2DRD3
SCHEMBL21509722 0.84 AKR1C3 (0.49) HPGDHRH3AKR1C3CCR6NPC1
SCHEMBL14525387 0.83 AKR1C3 (0.48) HPGDHRH3AKR1C3
SCHEMBL20203463 0.82 ALDH1A1 (0.38) HRH3DRD3KCNH2CDK4CCND1
SCHEMBL2820867 0.81 HPGD (0.42) HPGDHRH3AKR1C3CACNA2D1SLC6A2
SCHEMBL20203604 0.80 AKR1C3 (0.36) HRH3AKR1C3NPC1RAB9ADRD3
SCHEMBL20203473 0.80 HTR6 (0.40) HRH3AKR1C3CACNA2D1SLC6A2ESR1
SCHEMBL10255132 0.77 MAPT (0.46) NPC1RAB9ACDK4CCND3CDK9
SCHEMBL27446401 0.77 PIM1 (0.36) DRD3KCNH2ESR1
SCHEMBL14525385 0.75 PTGS2 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 EP disclosed
EP-3546458-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2019-10-02 EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 HPGD 1256/4885HRH3 2223/4885AKR1C3 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.